Key facts
- This page summarizes Jean-Pierre Sommadossi's Form 4 filing for Atea Pharmaceuticals, Inc. (AVIR).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 03 Feb 2026, 19:46.
Jean-Pierre Sommadossi - 31 Jan 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)
- Reporting relationship
- President, CEO, and Chairman, Director
- Issuer ticker
- AVIR
- Reported as of
- 31 Jan 2026
- Net transaction value
- -$77,834
- SEC form
- 4
- Accepted by SEC
- 03 Feb 2026, 19:46:07 UTC
- Prior SEC filing
- 04 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jean-Pierre Sommadossi filed Form 4 for Atea Pharmaceuticals, Inc. (AVIR) on 03 Feb 2026.
Change
- Previous filing in this sequence was filed on 04 Feb 2025.
- Current net transaction value: -$77,834.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001296995
Primary reporting owner
Sommadossi Jean-Pierre
- Relationship
- President, CEO, and Chairman, Director
- Address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON
- Signature
- /s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
- Signature date
- 03 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVIR
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +272,983
- Change %
- +91%
- Price
- Shares after
- 573,923
- Date
- 31 Jan 2026
- Ownership
- Direct
- Footnotes
- F1
AVIR
transaction
Common Stock
Tax liability
- Transaction value
- $449,834
- Shares
- -106,093
- Change %
- -18%
- Price
- $4.24
- Shares after
- 467,830
- Date
- 31 Jan 2026
- Ownership
- Direct
AVIR
transaction
Common Stock
Options Exercise
- Transaction value
- $372,000
- Shares
- +300,000
- Change %
- +64%
- Price
- $1.24
- Shares after
- 767,830
- Date
- 03 Feb 2026
- Ownership
- Direct
AVIR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 5,866,025
- Date
- 31 Jan 2026
- Ownership
- Held by JPM Partners LLC
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVIR
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -173,466
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 31 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 173,466
- Exercise price
- Footnotes
- F1, F2
AVIR
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -99,517
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 31 Jan 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 99,517
- Exercise price
- Footnotes
- F1, F3, F4
AVIR
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -300,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 03 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 300,000
- Exercise price
- $1.24
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F2
The original grant of 520,400 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
Footnote F3
Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
Footnote F4
Reflected one (1) share correction due to prior administrative rounding error with respect to RSU vesting in 2026.
Footnote F5
The option is fully vested and exercisable.